Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: Isodiol rising

After cannabis stocks consolidated over a quiet summer, many of these stocks are once again powering higher. For both Stockhouse readers and Bullboard users, it may seem like “all cannabis, all the time” at the moment. But that’s where inv...

Kardashian-Style News Bomb: Already Big Ashram Gets Bigger And Bigger

Bigger is Better (at least in this respect) What a pleasant surprise! The Ashram Rare Earth and Fluorspar Deposit continues to grow. As announced today by Commerce Resources Corp. , recent core assays for vertical drilling at Ashram has disc...

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure ...

How Well are Cannabis Stocks Performing in the Market?

At this time last year, cannabis stock was considered to be the hottest investment trend on Wall Street as Canada lifted the veil of recreational marijuana, and it was legally approved for sale for adult-use, on Oct 2018. Investors were hoping legal weed sales would grow t...

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. Vancouver-based clinical stage biopharmaceutical company InMed Pharmaceuticals Inc. (IN:TSX; IMLFF:OTCQX) , which is engaged in...

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch

Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. Arcadia Biosciences Inc. (RKDA:NASDAQ) , which employs science-based approac...

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

The study data and their implications are provided in a BTIG report. In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are "as hoped" from Esperion Therapeutics Inc.'s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezet...

Cypress Development Delivers Strong PFS on Clayton Valley Lithium Project

Cypress Development Corp. (CYP:TSX.V; CYDVF:OTCQB; C1Z1:FSE) owns 100% of a giant, leachable, lithium-bearing claystone-hosted resource, the Clayton Valley Lithium Project (CVLP), adjacent to Albemarle Corp.'s Silver Peak brine operations in Nevada. The company has an En...

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. ...

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
1 2 3 4 5 6